Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

Deenan Pillay

    Research output: Contribution to journalReview article

    199 Citations (Scopus)

    Abstract

    Viral drug susceptibility is associated with virologic response to new treatments. Standardized drug resistance tests are now available, and data from some clinical trials suggest that the use of drug resistance testing may be associated with improved virologic outcome. However, drug resistance testing is complex in terms of performance, interpretation and clinical application. HIV-1 drug resistance testing is used across Europe in patient management, but not in a consistent manner. This is due to differences in the national approaches to treatment, treatment management and reimbursement, as well as availability of tests. National guidelines only exist in some countries. In addition, the laboratory quality assurance and quality control standards are not applied uniformly. The EuroGuidelines Group was established to formulate clinical as well as laboratory guidelines for the use of HIV-1 drug resistance testing that are specific for the European setting. The group is comprised of academic clinicians and virologists, scientist from the industry and representatives of the patient community. The panel of experts will review these guidelines and update them on a yearly basis as new scientific evidence becomes available. (C) 2001 Lippincott Williams & Wilkins.
    Original languageEnglish
    Pages (from-to)309-320
    Number of pages12
    JournalAids
    Volume15
    Issue number3
    DOIs
    Publication statusPublished - 1 Feb 2001

    Keywords

    • HIV-1 drug susceptibility
    • reverse transcriptase inhibitors
    • protease inhibitors
    • antiretroviral therapy
    • drug resistance
    • genotype
    • phonotype

    Fingerprint

    Dive into the research topics of 'Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting'. Together they form a unique fingerprint.

    Cite this